Serious Adverse Drug Reactions Associated with Off-Label and Unlicensed Drug Use in Children: A 14-Year Analysis of VigiBase Reports from Serbia
Abstract
Background/Objectives: Adverse drug reactions are associated with off-label (OL) and unlicensed (UL) drug use in children. Methods: We conducted a retrospective observational pharmacovigilance study based on individual case safety reports (ICSRs) and adverse drug reactions (ADRs) from VigiBase for patients aged 0-17 years to evaluate reporting patterns associated with off-label and unlicensed suspected drugs reported in Serbia. Results: Over 14 years, 2037 pediatric ICSRs comprising 4257 ADRs were reported. Infants (28 days-23 months) accounted for just over half of ICSRs, and systemic anti-infectives and vaccines dominated suspected drugs. Overall, 9.7% of ADRs were serious, including 12 fatal outcomes, with serious ADRs reported more often for non-vaccine than vaccine suspected drugs. Off-label and unlicensed suspected drug records accounted for 10.8% and 1.9% of suspected drug records, respectively, and had higher proportions of serious ADRs than on-label or licensed use (off-label 12.1% vs. on-label 9.4%, p = 0.04; unlicensed 22.9% vs. licensed 9.4%, p Conclusions: Although off-label and unlicensed drugs accounted for a minority of pediatric reports, they were associated with a higher proportion of serious reported ADRs, particularly in the neonatal period. These findings should be interpreted as pharmacovigilance reporting patterns rather than incidence-based estimates or proof of causality.
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.